
Sign up to save your podcasts
Or
After a long 18 months of living through a pandemic, vaccines have paved a way forward to a new normal – Just 6 weeks ago, the Pfizer vaccine received emergency use authorization for adolescents down to age 12; and here at Children’s Colorado, we are a Pfizer vaccine trial site for kids ages 5-11. As more of our pediatric patients become eligible for the vaccine, primary care providers will be considering how to safely vaccinate patients with a risk of allergic reaction. In this episode, we will talk about the incidence, suspected epidemiology and current policy related to allergic reactions to the SARS-CoV-2 vaccines and steps for avoiding potential adverse reactions.
Today's guest is Dr. Matt Greenhawt, Director of the Food Challenge and Research Unit at Children’s Hospital Colorado and Associate Professor of Pediatrics, Section of Allergy & Immunology at the University of Colorado School of Medicine.
Do you have thoughts about today's episode or suggestions for a future topic? Write to us, [email protected]
3
22 ratings
After a long 18 months of living through a pandemic, vaccines have paved a way forward to a new normal – Just 6 weeks ago, the Pfizer vaccine received emergency use authorization for adolescents down to age 12; and here at Children’s Colorado, we are a Pfizer vaccine trial site for kids ages 5-11. As more of our pediatric patients become eligible for the vaccine, primary care providers will be considering how to safely vaccinate patients with a risk of allergic reaction. In this episode, we will talk about the incidence, suspected epidemiology and current policy related to allergic reactions to the SARS-CoV-2 vaccines and steps for avoiding potential adverse reactions.
Today's guest is Dr. Matt Greenhawt, Director of the Food Challenge and Research Unit at Children’s Hospital Colorado and Associate Professor of Pediatrics, Section of Allergy & Immunology at the University of Colorado School of Medicine.
Do you have thoughts about today's episode or suggestions for a future topic? Write to us, [email protected]
38,569 Listeners
90,779 Listeners
38,115 Listeners
86,348 Listeners
111,487 Listeners
56,155 Listeners
68,684 Listeners
228 Listeners
313 Listeners
57,599 Listeners
777 Listeners
15,283 Listeners
10,172 Listeners
21,131 Listeners
417 Listeners